These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
686 related articles for article (PubMed ID: 29992895)
1. Nanovehicle-based Small Interfering RNA (siRNA) Delivery for Therapeutic Purposes: A New Molecular Approach in Pharmacogenomics. Akhtari J; Tafazoli A; Mehrad-Majd H; Mahrooz A Curr Clin Pharmacol; 2018; 13(3):173-182. PubMed ID: 29992895 [TBL] [Abstract][Full Text] [Related]
2. Tumor-targeting multifunctional nanoparticles for siRNA delivery: recent advances in cancer therapy. Ku SH; Kim K; Choi K; Kim SH; Kwon IC Adv Healthc Mater; 2014 Aug; 3(8):1182-93. PubMed ID: 24577795 [TBL] [Abstract][Full Text] [Related]
3. Nanoengineered strategies for siRNA delivery: from target assessment to cancer therapeutic efficacy. Mishra DK; Balekar N; Mishra PK Drug Deliv Transl Res; 2017 Apr; 7(2):346-358. PubMed ID: 28050890 [TBL] [Abstract][Full Text] [Related]
4. Therapeutic potentials of gene silencing by RNA interference: principles, challenges, and new strategies. Deng Y; Wang CC; Choy KW; Du Q; Chen J; Wang Q; Li L; Chung TK; Tang T Gene; 2014 Apr; 538(2):217-27. PubMed ID: 24406620 [TBL] [Abstract][Full Text] [Related]
5. RNA interference-based therapy and its delivery systems. Chen X; Mangala LS; Rodriguez-Aguayo C; Kong X; Lopez-Berestein G; Sood AK Cancer Metastasis Rev; 2018 Mar; 37(1):107-124. PubMed ID: 29243000 [TBL] [Abstract][Full Text] [Related]
6. Nanoparticle-siRNA: A potential cancer therapy? Young SW; Stenzel M; Yang JL Crit Rev Oncol Hematol; 2016 Feb; 98():159-69. PubMed ID: 26597018 [TBL] [Abstract][Full Text] [Related]
7. Development of RNAi technology for targeted therapy--a track of siRNA based agents to RNAi therapeutics. Zhou Y; Zhang C; Liang W J Control Release; 2014 Nov; 193():270-81. PubMed ID: 24816071 [TBL] [Abstract][Full Text] [Related]
8. Bio-inspired materials in drug delivery: Exploring the role of pulmonary surfactant in siRNA inhalation therapy. De Backer L; Cerrada A; Pérez-Gil J; De Smedt SC; Raemdonck K J Control Release; 2015 Dec; 220(Pt B):642-50. PubMed ID: 26363301 [TBL] [Abstract][Full Text] [Related]
10. Strategies for in vivo delivery of siRNAs: recent progress. Higuchi Y; Kawakami S; Hashida M BioDrugs; 2010 Jun; 24(3):195-205. PubMed ID: 20462284 [TBL] [Abstract][Full Text] [Related]
11. Small interfering RNAs (siRNAs) in cancer therapy: a nano-based approach. Mahmoodi Chalbatani G; Dana H; Gharagouzloo E; Grijalvo S; Eritja R; Logsdon CD; Memari F; Miri SR; Rad MR; Marmari V Int J Nanomedicine; 2019; 14():3111-3128. PubMed ID: 31118626 [TBL] [Abstract][Full Text] [Related]
12. siRNA therapeutics in the treatment of diseases. Bakhtiyari S; Haghani K; Basati G; Karimfar MH Ther Deliv; 2013 Jan; 4(1):45-57. PubMed ID: 23323780 [TBL] [Abstract][Full Text] [Related]
13. Brain Targeting of siRNA via Intranasal Pathway. Mohanty C; Kundu P; Sahoo SK Curr Pharm Des; 2015; 21(31):4606-13. PubMed ID: 26486146 [TBL] [Abstract][Full Text] [Related]
14. Delivery and biodistribution of siRNA for cancer therapy: challenges and future prospects. Seth S; Johns R; Templin MV Ther Deliv; 2012 Feb; 3(2):245-61. PubMed ID: 22834200 [TBL] [Abstract][Full Text] [Related]
15. The design and exogenous delivery of siRNA for post-transcriptional gene silencing. Gilmore IR; Fox SP; Hollins AJ; Sohail M; Akhtar S J Drug Target; 2004 Jul; 12(6):315-40. PubMed ID: 15545082 [TBL] [Abstract][Full Text] [Related]
16. Systemic delivery of siRNA by aminated poly(α)glutamate for the treatment of solid tumors. Polyak D; Krivitsky A; Scomparin A; Eliyahu S; Kalinski H; Avkin-Nachum S; Satchi-Fainaro R J Control Release; 2017 Jul; 257():132-143. PubMed ID: 27356019 [TBL] [Abstract][Full Text] [Related]
17. In vivo delivery of small interfering RNA to tumors and their vasculature by novel dendritic nanocarriers. Ofek P; Fischer W; Calderón M; Haag R; Satchi-Fainaro R FASEB J; 2010 Sep; 24(9):3122-34. PubMed ID: 20385622 [TBL] [Abstract][Full Text] [Related]
18. Significance and applications of nanoparticles in siRNA delivery for cancer therapy. Ali HM; Urbinati G; Raouane M; Massaad-Massade L Expert Rev Clin Pharmacol; 2012 Jul; 5(4):403-12. PubMed ID: 22943120 [TBL] [Abstract][Full Text] [Related]
19. Gene silencing through RNA interference (RNAi) in vivo: strategies based on the direct application of siRNAs. Aigner A J Biotechnol; 2006 Jun; 124(1):12-25. PubMed ID: 16413079 [TBL] [Abstract][Full Text] [Related]
20. Improving siRNA bio-distribution and minimizing side effects. Scaggiante B; Dapas B; Farra R; Grassi M; Pozzato G; Giansante C; Fiotti N; Grassi G Curr Drug Metab; 2011 Jan; 12(1):11-23. PubMed ID: 21222588 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]